21 October 2022 | Other

Immune response from Moderna's updated Omicron vaccine persists for 3 months

Moderna Inc's COVID-19 booster vaccine, aimed at the BA.1 Omicron strain, elicits a powerful immune reaction against this subvariant, keeping antibodies at a high level for at least three months, as reported by the company.

The vaccine developed by Moderna against the Omicron variant has already received regulatory approval in a number of countries.

Stephane Bancel, Chief Executive Officer of Moderna Inc, said that clinical trials have shown an excellent immune response, which has been achieved with the help of a bivalent booster and retains its effect for at least 3 months.

The company also noted that the data regarding the trials of its target vaccine BA.4/BA.5 in humans are expected later this year.

Company MarketCheese
Period: 25.02.2026 Expectation: 3000 pips
Accumulated positions near key support are signal to buy Tesla stock
Yesterday at 10:19 AM 38
Lyra_Moonwell1
Lyra_Moonwell1

Listed among the best MarketCheese authors
1st in the segment "Oil and gas"
Period: 25.02.2026 Expectation: 8400 pips
Fed pressure and lackluster demand drive Bitcoin selloff
Yesterday at 07:03 AM 26
Period: 31.03.2026 Expectation: 240 pips
SPX selloff targets 6,660
Yesterday at 06:44 AM 23
Brent neutral
Period: 30.04.2026 Expectation: 400 pips
Selling Brent crude down to $65.0
Yesterday at 03:26 AM 23
Period: 31.03.2026 Expectation: 1000 pips
Investing in SPX with $6,920 in sight
Yesterday at 03:26 AM 14
Period: 24.02.2026 Expectation: 1210 pips
SPX finds solid ground after recent selloff
16 February 2026 23
Lyra_Moonwell1
Lyra_Moonwell1

Listed among the best MarketCheese authors
1st in the segment "Oil and gas"
Go to forecasts